SILVER SPRING, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it...
Tzioupis, C. & Giannoudis, P. V. Prevalence of long-bone non-unions. Injury 38, S3–S9 (2007).Article PubMed Google Scholar Calori, G. M., Mazza, E., Colombo,...
The first IL-23p19 targeted biologic recommended by the National Institute for Health and Care Excellence (NICE) for moderately to severely active ulcerative colitis (UC)...
The New York Times just broke a story on Burst Biologics and Weill Cornell that fits with long-standing troubling questions about regenerative biologics producers....
Elia, I. & Haigis, M. C. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat. Metab. 3, 21–32 (2021).Article Google...
Oberweis, C. V., Marchal, J. A., López-Ruiz, E. & Gálvez-Martín, P. A worldwide overview of regulatory frameworks for tissue-based products. Tissue Eng. B 26,...
If approved, Novartis’ remibrutinib has potential to be the first of a new class of chronic spontaneous urticaria (CSU) treatment in a decade.
Positive top-line...
